|
|
| Line 1: |
Line 1: |
| {{drugbox-mab
| |
| | image =
| |
| | source = [[Human]]
| |
| | target =
| |
| | CAS_number =
| |
| | ATC_prefix =
| |
| | ATC_suffix =
| |
| | ATC_supplemental =
| |
| | PubChem =
| |
| | DrugBank =
| |
| | chemical_formula =
| |
| | molecular_weight =
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | pregnancy_category =
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| }}
| |
| '''Denosumab''' (formerly known as '''AMG 162''') is a [[human]] [[monoclonal antibody]] which is used to treat [[osteoporosis]].
| |
| Denosumab is designed to target RANK Ligand, a protein that acts as the primary signal to promote bone removal. In many bone loss conditions, RANK Ligand overwhelms the body's natural defense against bone destruction.
| |
|
| |
|
| {{monoclonal-antibody-stub}}
| |
| {{humanmonoclonals}}
| |
|
| |
| [[Category:Monoclonal antibodies]]
| |
| {{WikiDoc Sources}}
| |